GSK (LON:GSK) Earns Hold Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating reiterated by investment analysts at Deutsche Bank Aktiengesellschaft in a research note issued on Wednesday,Digital Look reports. They presently have a GBX 2,000 price target on the stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 6.61% from the company’s current price.

GSK has been the subject of a number of other reports. Citigroup reduced their price objective on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Wednesday, July 29th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of GBX 2,048.57.

GSK Stock Performance

Shares of GSK opened at GBX 1,876 on Wednesday. GSK has a 12-month low of GBX 1,288.61 and a 12-month high of GBX 2,282. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The company has a market cap of £75.15 billion, a PE ratio of 15.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The stock has a 50-day moving average price of GBX 1,939.08 and a 200-day moving average price of GBX 1,998.43.

GSK (LON:GSK) last announced its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. As a group, equities analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Vishal Sikka acquired 1,266 shares of the stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of GBX 5,069 per share, with a total value of £64,173.54. Also, insider Jonathan Symonds bought 1,550 shares of the business’s stock in a transaction dated Friday, June 19th. The shares were bought at an average cost of GBX 1,935 per share, for a total transaction of £29,992.50. Insiders purchased 3,618 shares of company stock valued at $13,481,942 in the last ninety days. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.